Use of Pregabalin - A Nationwide Pharmacoepidemiological Drug Utilization Study with Focus on Abuse Potential

Pharmacopsychiatry

Volumn 49, Issue 4, 2016, Pages 155-161

  Schjerning, O ^a,b   Pottegard A ^c   Damkier, P ^c,d   Rosenzweig, M ^e   Nielsen, J ^a,b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e Danish Health and Medicines Authority   (Denmark)

Author keywords

Abuse; Denmark; Drug utilization; Pregabalin

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OPIATE; PREGABALIN; PSYCHOSTIMULANT AGENT; ANTICONVULSIVE AGENT;

ADULT; ARTICLE; DRUG ABUSE; DRUG EXPOSURE; DRUG POTENCY; DRUG UTILIZATION; FEMALE; FOLLOW UP; HUMAN; ICD-10; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCRIPTION; PRIORITY JOURNAL; AGE DISTRIBUTION; AGED; DENMARK; DOSE RESPONSE; PREDICTIVE VALUE; PRESCRIPTION DRUG MISUSE; RETROSPECTIVE STUDY; STATISTICAL MODEL; SUBSTANCE-RELATED DISORDERS;

ADULT; AGE DISTRIBUTION; AGED; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; DENMARK; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREGABALIN; PRESCRIPTION DRUG MISUSE; RETROSPECTIVE STUDIES; SUBSTANCE-RELATED DISORDERS;

EID: 84960411485     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0042-101868     Document Type: Article

References (34)

1. Halaby A., Kassam S. A., Naja W. J. Pregabalin dependence: a case report. Curr Drug Saf: 2014; 10.2174/1574886309666141022101956
2. Cho Y. W., Song M. L. Effects of pregabalin in patients with hypnotic-dependent insomnia. J Clin Sleep Med: 2014; 10 545 550
3. Oulis P., Kalogerakou S., Anyfandi E. et al. Cognitive effects of pregabalin in the treatment of long-term benzodiazepine-use and dependence. Hum Psychopharmacol: 2014; 29 224 229
4. Guglielmo R., Martinotti G., Clerici M. et al. Pregabalin for alcohol dependence: a critical review of the literature. Adv Ther: 2012; 29 947 957
5. Gahr M., Franke B., Freudenmann R. W. et al. Concerns about pregabalin: further experience with its potential of causing addictive behaviors. J Addict Med: 2013; 7 147 149
6. Chalabianloo F., Schjott J. Pregabalin and its potential for abuse. Tidsskr Nor Laegeforen: 2009; 129 186 187
7. Schjerning O., Rosenzweig M., Pottegard A. et al. Abuse potential of pregabalin: a systematic review. CNS Drugs. 2016; 10.1007/s40263-015-0303-6
8. Zaccara G., Gangemi P., Perucca P. et al. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia: 2011; 52 826 836
9. Papazisis G., Garyfallos G., Sardeli C. et al. Pregabalin abuse after past substance-seeking behavior. Int J Clin Pharmacol Ther: 2013; 51 441 442
10. Halaby A., Kassm S. A., Naja W. J. Pregabalin dependence: a case report. Curr Drug Saf: 2015; 10 184 186
11. Jonsson B., Backman E., Salmonson H. et al. Injection of crushed tablets - a prospective observational study. Clin Toxicol (Phila): 2014; 52 982 983
12. Carrus D., Schifano F. Pregabalin misuse-related issues; intake of large dosages, drug-smoking allegations, and possible association with myositis: two case reports. J Clin Psychopharmacol: 2012; 32 839 840
13. Grosshans M., Lemenager T., Vollmert C. et al. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol: 2013; 69 2021 2025
14. Boden R., Wettermark B., Brandt L. et al. Factors associated with pregabalin dispensing at higher than the approved maximum dose. Eur J Clin Pharmacol: 2014; 70 197 204
15. Nose M., Tansella M., Thornicroft G. et al. Is the Defined Daily Dose system a reliable tool for standardizing antipsychotic dosages? International clinical psychopharmacology: 2008; 23 287 290
16. Hallas J., Nissen A. Individualized drug utilization statistics. Analysing a population's drug use from the perspective of individual users. Eur J Clin Pharmacol: 1994; 47 367 372
17. Hallas J., Stovring H. Templates for analysis of individual-level prescription data. Basic Clin Pharmacol Toxicol: 2006; 98 260 265
18. Birt J., Johnston J., Nelson D. Exploration of claims-based utilization measures for detecting potential nonmedical use of prescription drugs. J Manag Care Spec Pharm: 2014; 20 639 646
19. Nielsen J., Roge R., Schjerning O. et al. Geographical and temporal variations in clozapine prescription for schizophrenia. Eur Neuropsychopharmacol: 2012; 22 818 824
20. Wallach-Kildemoes H., Skovgaard A. M., Thielen K. et al. Social adversity and regional differences in prescribing of ADHD medication for school-age children. J Dev Behav Pediatr: 2015; 36 330 341
21. Pottegard A., Bjerregaard B. K., Glintborg D. et al. The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a national perspective. Eur J Clin Pharmacol: 2012; 68 1443 1450
22. Henriksen D. P., Rasmussen L., Hansen M. R. et al. Comparison of the five Danish regions regarding demographic characteristics, healthcare utilization, and medication use - a descriptive cross-sectional study. PLoS One: 2015; 10 e0140197
23. Freedman B. M., O'Hara E. Pregabalin has opioid-sparing effects following augmentation mammaplasty. Aesthet Surg J: 2008; 28 421 424
24. Kammerer N., Lemenager T., Grosshans M. et al. Pregabalin for the reduction of opiate withdrawal symptoms. Psychiatr Prax: 2012; 39 351 352
25. Hadley S. J., Mandel F. S., Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol: 2012; 26 461 470
26. Oulis P., Masdrakis V. G., Karakatsanis N. A. et al. Pregabalin in the discontinuation of long-term benzodiazepine use: a case-series. Int Clin Psychopharmacol: 2008; 23 110 112
27. Ben-Menachem E. Weight issues for people with epilepsy - a review. Epilepsia: 2007; 48 09 42 45
28. Yargic I., Ozdemiroglu F. A. Pregabalin abuse: a case report/Pregabalin kötüye kullanlml: Bir olgu sunumu. Klinik Psikofarmakoloji Bülteni/Bulletin of Clinical Psychopharmacology: 2011; 10.5350/kpb-bcp201121110: 64 66
29. Skopp G., Zimmer G. Pregabalin - a drug with abuse potential? Arch Kriminol: 2012; 229 44 54
30. Grosshans M., Mutschler J., Hermann D. et al. Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiatry: 2010; 167 869
31. Rutten K., De Vry J., Robens A. et al. Dissociation of rewarding, anti-aversive and anti-nociceptive effects of different classes of anti-nociceptives in the rat. Eur J Pain: 2011; 15 299 305
32. Andrews N., Loomis S., Blake R. et al. Effect of gabapentin-like compounds on development and maintenance of morphine-induced conditioned place preference. Psychopharmacology (Berl): 2001; 157 381 387
33. Filipetto F. A., Zipp C. P., Coren J. S. Potential for pregabalin abuse or diversion after past drug-seeking behavior. J Am Osteopath Assoc: 2010; 110 605 607
34. Kapil V., Green J. L., Le Lait M-C et al. Misuse of the γ-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. British Journal of Clinical Pharmacology: 2014; 78 190 191